Shares of Vericel Corp (NASDAQ:VCEL) have earned a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $14.00.
A number of equities research analysts recently weighed in on the company. BTIG Research restated a “buy” rating and set a $13.00 price objective (up from $8.00) on shares of Vericel in a research note on Monday, March 5th. ValuEngine upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Piper Jaffray Companies restated an “overweight” rating and set a $9.00 price objective on shares of Vericel in a research note on Tuesday, January 2nd. BidaskClub upgraded Vericel from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Finally, Ladenburg Thalmann Financial Services cut Vericel from a “buy” rating to a “neutral” rating in a research note on Tuesday.
A number of institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its stake in Vericel by 13.8% in the second quarter. Bank of New York Mellon Corp now owns 37,202 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 4,523 shares during the last quarter. Perkins Capital Management Inc. raised its stake in Vericel by 2.9% in the fourth quarter. Perkins Capital Management Inc. now owns 578,950 shares of the biotechnology company’s stock valued at $3,155,000 after buying an additional 16,350 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in Vericel in the fourth quarter valued at about $105,000. Bank of Montreal Can purchased a new stake in Vericel in the fourth quarter valued at about $140,000. Finally, Geode Capital Management LLC raised its stake in Vericel by 11.9% in the fourth quarter. Geode Capital Management LLC now owns 255,168 shares of the biotechnology company’s stock valued at $1,390,000 after buying an additional 27,226 shares during the last quarter. Institutional investors own 38.49% of the company’s stock.
Shares of Vericel (VCEL) traded down $0.25 during midday trading on Wednesday, hitting $11.55. The company had a trading volume of 1,834,042 shares, compared to its average volume of 1,335,657. The company has a quick ratio of 2.22, a current ratio of 3.86 and a debt-to-equity ratio of 0.75. The stock has a market cap of $426.02, a PE ratio of -21.79 and a beta of 3.15. Vericel has a 1 year low of $2.35 and a 1 year high of $12.80.
Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Monday, March 5th. The biotechnology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.13. The firm had revenue of $23.35 million during the quarter. Vericel had a negative return on equity of 98.77% and a negative net margin of 27.04%. analysts predict that Vericel will post -0.31 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Vericel Corp (VCEL) Receives $14.00 Consensus PT from Analysts” was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/03/17/vericel-corp-vcel-receives-14-00-consensus-pt-from-analysts.html.
Vericel Company Profile
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.